Integrative Peptide Therapy — Clinical Reference Protocol (Demo Import)
physician_protocol · expert_opinion · status: needs_provider_review
Metadata
Summary (generated — provider review required)
Integrative Peptide Therapy — Clinical Reference Protocol Tissue Repair & Recovery. BPC-157 250 mcg subcutaneous twice daily for 4 weeks, then 250 mcg once daily for maintenance. Reconstitute with bacteriostatic water and refrigerate after mixing.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (16) · phenotypes (1)
evidence_reference, dosing_reference, contraindication_reference, monitoring_reference, safety_reference
Phenotypes: connective_tissue
Evidence claims (17) · review items (13)
dosing · pending
BPC-157 250 mcg subcutaneous twice daily for 4 weeks, then 250 mcg once daily for maintenance.
dosing · pending
TB-500 / TB4 2 mg subcutaneous twice weekly for 6 weeks.
contraindication · pending
These agents may cause transient injection-site reactions and lightheadedness; they are contraindicated in patients with active malignancy.
monitoring · pending
Monitor inflammatory markers including hs-CRP at baseline and every 4 weeks.
dosing · pending
KPV 500 mcg subcutaneous daily, or 500 mcg orally twice daily for gut-directed support, for 8 weeks.
safety · pending
KPV is generally well tolerated; avoid in pregnancy and lactation due to insufficient safety data.
monitoring · pending
Follow-up labs should include a comprehensive metabolic panel.
dosing · pending
CJC-1295 100 mcg subcutaneous nightly at bedtime, five nights on and two nights off, for 12 weeks.
dosing · pending
Ipamorelin 200 mcg subcutaneous nightly.
contraindication · pending
This combination may cause water retention, flushing, and tingling; use caution in patients with insulin resistance and contraindicated in active cancer.
monitoring · pending
Monitor IGF-1 and fasting glucose at baseline, week 6, and week 12.
dosing · pending
MOTS-c 10 mg subcutaneous three times weekly for 4 weeks.
dosing · pending
SS-31 (elamipretide) dosing per provider judgment.
safety · pending
Risk of injection-site irritation.
monitoring · pending
Monitor exercise tolerance and follow-up labs.
dosing · pending
GHK-Cu 2 mg subcutaneous daily for 30 days for skin and connective tissue.
dosing · pending
LL-37 50 mcg subcutaneous every other day; LL-37 has antimicrobial and immunomodulatory properties and may cause injection-site inflammation.
Extracted chunks (2)
278 approx tokens across 2 chunks.